Cell and gene therapies are still struggling to break through. Their therapeutic value is clear, but the rollout — for hospitals, insurers, doctors, and patients — is still slow going. We’ll gather experts to explore the new and emerging treatments and unpack the business strategies that might keep the industry moving forward.